Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of RLY-4008 in intrahepatic cholangiocarcinoma and other advanced solid tumors
2024-512622-29-00Phase 2Completed
- Sponsor
- Elevar Therapeutics
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label trial of lirafugratinib in intrahepatic cholangiocarcinoma (ICC) and Nonhematologic neoplasms (4 arms), sponsored by Elevar Therapeutics. Primary endpoints: Maximum tolerated dose and recommended Phase 2 dose, Overall safety profile and 2 more. Started Sep 2021; status: completed.
02
Drugs
lirafugratinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-512622-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512622-29-00.